1
|
Raab MS, Zamagni E, Manier S, Rodriguez‐Otero P, Schjesvold F, Broijl A. Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results. EJHAEM 2023; 4:1117-1131. [PMID: 38024633 PMCID: PMC10660429 DOI: 10.1002/jha2.743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 05/31/2023] [Accepted: 06/13/2023] [Indexed: 12/01/2023]
Abstract
Overall outcomes for multiple myeloma have improved due to the availability of new therapies, but patients with relapsed/refractory multiple myeloma harbouring certain factors continue to pose a therapeutic challenge. These challenging features include high-risk cytogenetics, renal impairment, patient characteristics such as age and frailty, and extramedullary disease. Prior refractory status and number of prior lines add further complexity to the treatment of these patients. While newer regimens are available and have suggested efficacy in these patient populations through subgroup analyses, differences in trial definitions and cut-offs make meaningful comparisons difficult. This review aims to examine the available clinical trial data for patients with high-risk cytogenetics, renal impairment, age and frailty and extramedullary disease.
Collapse
Affiliation(s)
- Marc S. Raab
- Heidelberg Myeloma Center, Department of Medicine VUniversity HospitalHeidelbergGermany
| | - Elena Zamagni
- Seragnoli Institute of HematologyBologna University School of MedicineBolognaItaly
| | - Salomon Manier
- Department of HematologyUniversity Hospital Center of LilleLilleFrance
| | | | - Fredrik Schjesvold
- Oslo Myeloma Center, Department of HaematologyOslo University Hospital, Oslo, Norway, and KG Jebsen Center for B Cell MalignanciesUniversity of OsloOsloNorway
| | - Annemiek Broijl
- Department of HematologyErasmus MC Cancer InstituteRotterdamThe Netherlands
| |
Collapse
|
2
|
Britto J, Seow H, Pond GR, Wildes TM, McCurdy A, Visram A, Ebraheem M, Aljama M, Gayowsky A, Mian H. Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis. J Geriatr Oncol 2023; 14:101592. [PMID: 37479538 DOI: 10.1016/j.jgo.2023.101592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 06/12/2023] [Accepted: 07/13/2023] [Indexed: 07/23/2023]
Affiliation(s)
- Joanne Britto
- Department of Oncology, McMaster University, Hamilton, Canada
| | - Hsien Seow
- Department of Oncology, McMaster University, Hamilton, Canada
| | - Gregory R Pond
- Department of Oncology, McMaster University, Hamilton, Canada
| | - Tanya M Wildes
- Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Arleigh McCurdy
- The Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, Canada
| | - Alissa Visram
- The Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, Canada
| | | | - Mohammed Aljama
- Department of Oncology, McMaster University, Hamilton, Canada
| | | | - Hira Mian
- Department of Oncology, McMaster University, Hamilton, Canada.
| |
Collapse
|
3
|
Huynh L, Birsen R, Mora L, Couderc AL, Mitha N, Farcet A, Chebib A, Chaibi P. Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature. Cancers (Basel) 2022; 14:cancers14194741. [PMID: 36230662 PMCID: PMC9564122 DOI: 10.3390/cancers14194741] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Revised: 09/19/2022] [Accepted: 09/25/2022] [Indexed: 11/16/2022] Open
Abstract
Data on octogenarian patients with MM are scarce, and optimal management remains controversial. We report a retrospective cohort of unselected octogenarian patients with NDMM treated with bortezomib dexamethasone (Vd). Seventy-four patients were treated with an initial doublet therapy (Vd regimen, 2−3 cycles, induction). A dose escalation with an adjunction of melphalan or cyclophosphamide was proposed for patients who had an insufficient response after induction and who could tolerate it. In responders, the treatment was continued until progression or a plateau response for 6 months (consolidation). The overall response rate was 73%. After a median follow-up of 31.4 months, median progression-free survival (PFS) and overall survival (OS) were 13.2 and 26.9 months, respectively. PFS and OS of patients with ECOG PS < 3 (25.4 and 54.9 months, respectively) were better in comparison to PFS and OS of patients with ECOG PS ≥ 3 (9.3 and 11.3 months, respectively). Thirteen patients (17.6%) died during induction. Twelve patients (16.2%) died during consolidation. In conclusion, a conservative therapeutic strategy based on Vd resulted in a good response rate. However, the survival remains poor in the population of patients with an ECOG PS ≥ 3, mainly because of early mortality not related to progressive disease.
Collapse
Affiliation(s)
- Laurence Huynh
- Service d’Hématologie et Oncologie Gériatrique, Hôpital Charles Foix, APHP, 94200 Ivry Sur Seine, France
- Correspondence:
| | - Rudy Birsen
- Service d’Hématologie, Hôpital Cochin, APHP, Université de Paris Cité, 75014 Paris, France
| | - Lucie Mora
- Service d’Hématologie et Oncologie Gériatrique, Hôpital Charles Foix, APHP, 94200 Ivry Sur Seine, France
| | - Anne-Laure Couderc
- Service d’Hématologie et Oncologie Gériatrique, Hôpital Charles Foix, APHP, 94200 Ivry Sur Seine, France
| | - Nathalie Mitha
- Service d’Hématologie et Oncologie Gériatrique, Hôpital Charles Foix, APHP, 94200 Ivry Sur Seine, France
| | - Anaïs Farcet
- Service d’Hématologie et Oncologie Gériatrique, Hôpital Charles Foix, APHP, 94200 Ivry Sur Seine, France
| | - Amale Chebib
- Service d’Hématologie et Oncologie Gériatrique, Hôpital Charles Foix, APHP, 94200 Ivry Sur Seine, France
| | - Pascal Chaibi
- Service d’Hématologie et Oncologie Gériatrique, Hôpital Charles Foix, APHP, 94200 Ivry Sur Seine, France
| |
Collapse
|
4
|
Mele G, Cascavilla N, Di Renzo N, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Palazzo G, Palumbo G, Reddiconto G, Rossini B, Specchia G, Musto P, Pastore D. Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'. Ann Hematol 2022; 101:1727-1739. [PMID: 35587825 DOI: 10.1007/s00277-022-04857-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 04/24/2022] [Indexed: 12/01/2022]
Abstract
We report herein a multicentre retrospective analysis of 192 consecutive patients with symptomatic refractory/relapsed multiple myeloma (RRMM) treated with daratumumab in combination with bortezomib or lenalidomide as salvage therapy at 9 haematological centres in Puglia. Choice of both regimens was based on previous treatment and/or physicians' preference. Considering the under-representation of older patients (very old patient ≥ 80 years) in clinical trials and the prognostic and predictive importance and value of frailty status, here, we further characterised the patient cohort by age. The overall response rate (ORR) was generally lower than what was previously reported in the CASTOR (ORR 72.6% vs 85%) and POLLUX (ORR 86.5% vs 93%) trials. The lower ORR in our analysis compared to the CASTOR and POLLUX trials could be related to a less selected population. Similarly, amongst very old patients, the ORR was encouraging: ORR to treatment with DVd (daratumumab + bortezomib + dexamethasone) was 66.7%, and ORR to treatment with DRd (daratumumab + lenalidomide + dexamethasone) was 92.3%. Median TTP (time to progression) was 10.8 months (1-year TTP: 44.7%; 2-year TTP: 25.3%) in the DVd group; median TTP was not reached in the DRd group (1-year TTP: 82.7%; 2-year TTP: 71.4%). Median OS (overall survival) was not reached either in the DRd group (1-year OS: 85.9%; 2-year OS: 73.7%) or the DVd group (1-year OS: 70.2%; 2-year OS: 58.9%).
Collapse
Affiliation(s)
- G Mele
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy.
| | - N Cascavilla
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - N Di Renzo
- Haematology, Ospedale V. Fazzi, Lecce, Italy
| | - A Guarini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - P Mazza
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - L Melillo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | - V Pavone
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Tarantini
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - P Curci
- University of Bari Medical School, Policlinico, Bari, Italy
| | - A P Falcone
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - C Germano
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - A Mele
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Palazzo
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - G Palumbo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | | | - B Rossini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - G Specchia
- University of Bari Medical School, Policlinico, Bari, Italy
| | - P Musto
- University of Bari Medical School, Policlinico, Bari, Italy
| | - D Pastore
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy
| |
Collapse
|
5
|
Lee HC, Ailawadhi S, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Omel JL, Dhalla M, Liu L, Joshi P, Abonour R. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect ® MM Registry. Blood Cancer J 2021; 11:134. [PMID: 34301916 PMCID: PMC8302734 DOI: 10.1038/s41408-021-00524-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 06/16/2021] [Accepted: 07/05/2021] [Indexed: 11/09/2022] Open
Affiliation(s)
- Hans C Lee
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | | | | | | | - Robert M Rifkin
- Rocky Mountain Cancer Centers US Oncology Research, Denver, CO, USA
| | | | - Mohit Narang
- Maryland Oncology Hematology, US Oncology Research, Columbia, MD, USA
| | | | | | | | - Lynne Wagner
- Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - James L Omel
- Myeloma Research Advocate/Advisor, Grand Island, NE, USA
| | | | - Liang Liu
- Bristol Myers Squibb, Princeton, NJ, USA
| | | | | | | |
Collapse
|
6
|
Ediriwickrama N, Oyebamiji T, Munisamy S, Garland P, Cuthill K, Benjamin R, Ceesay MM, Bowcock S. The combination of an inclusive novel agent treatment strategy, pre-emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients. Br J Haematol 2019; 186:e11-e13. [PMID: 30864155 DOI: 10.1111/bjh.15848] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Nadishani Ediriwickrama
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| | - Titi Oyebamiji
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| | - Sreetharan Munisamy
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| | - Paula Garland
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| | - Kirsty Cuthill
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| | - Reuben Benjamin
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| | - M Mansour Ceesay
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| | - Stella Bowcock
- Princess Royal University Hospital, King's College Hospital NHS Trust, Orpington, London, UK
| |
Collapse
|
7
|
Gavriatopoulou M, Fotiou D, Koloventzou U, Roussou M, Migkou M, Ntanasis-Stathopoulos I, Kanellias N, Ziogas DC, Panagiotidis I, Gika D, Eleutherakis-Papaiakovou E, Terpos E, Kastritis E, Dimopoulos MA. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma 2019; 60:619-628. [DOI: 10.1080/10428194.2018.1509323] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Maria Gavriatopoulou
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Despina Fotiou
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Ursula Koloventzou
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Maria Roussou
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Magdalini Migkou
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Ioannis Ntanasis-Stathopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Nikolaos Kanellias
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Dimitrios C. Ziogas
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Ioannis Panagiotidis
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Dimitra Gika
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | | | - Evangelos Terpos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Efstathios Kastritis
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | | |
Collapse
|
8
|
Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 2019; 94:E2-E5. [PMID: 30300461 DOI: 10.1002/ajh.25310] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 09/30/2018] [Accepted: 10/03/2018] [Indexed: 11/07/2022]
Affiliation(s)
- Neeraj Y. Saini
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Romil Patel
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Ankur Varma
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Qaiser Bashir
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Ruby Delgado
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Gabriela Rondon
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Uday R. Popat
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Chitra M. Hosing
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Yago Nieto
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Partow Kebriaei
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Amin M. Alousi
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Sairah Ahmed
- Department of Lymphoma and Myeloma; MD Anderson Cancer Center; Houston Texas
| | - Donna M. Weber
- Department of Lymphoma and Myeloma; MD Anderson Cancer Center; Houston Texas
| | - Sheeba K. Thomas
- Department of Lymphoma and Myeloma; MD Anderson Cancer Center; Houston Texas
| | - Hans C. Lee
- Department of Lymphoma and Myeloma; MD Anderson Cancer Center; Houston Texas
| | | | - Krina K. Patel
- Department of Lymphoma and Myeloma; MD Anderson Cancer Center; Houston Texas
| | - Robert Z. Orlowski
- Department of Lymphoma and Myeloma; MD Anderson Cancer Center; Houston Texas
| | - Richard E. Champlin
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| | - Muzaffar H. Qazilbash
- Department of Stem Cell Transplantation and Cellular Therapy; MD Anderson Cancer Center; Houston Texas
| |
Collapse
|
9
|
Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA. How I treat elderly patients with plasma cell dyscrasias. Aging (Albany NY) 2018; 10:4248-4268. [PMID: 30568029 PMCID: PMC6326666 DOI: 10.18632/aging.101707] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Accepted: 12/04/2018] [Indexed: 01/01/2023]
Abstract
Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders which are more prevalent in the older part of the population. The introduction of novel agents, improved understanding of disease biology and better supportive management have improved outcomes considerably and in the era of the aging population the question of how to best manage older patients with plasma cell dyscrasias has never been more relevant. Data on how to treat these patients comes mostly from subgroup analysis as they are underrepresented in clinical trials. This review will cover issues, available evidence and recommendations relevant to diagnosis and management of the older patients with Multiple Myeloma (MM), Waldenstrom Macroglobulinemia (WM) and systemic AL Amyloidosis. What will become increasingly evident is the need to develop and establish the use of disease-specific geriatric assessment (GA) tools. Frailty status assessment using GA tools and moving away from making decisions based merely on chronological age will allow setting clear treatment goals and consequently achieving an optimum balance between effectiveness and toxicity for this complex and heterogeneous group of patients.
Collapse
Affiliation(s)
- Maria Gavriatopoulou
- Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Equal contribution
| | - Despoina Fotiou
- Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Equal contribution
| | - Ioannis Ntanasis-Stathopoulos
- Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
| | - Efstathios Kastritis
- Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
| | - Evangelos Terpos
- Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
| | - Meletios Athanasios Dimopoulos
- Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
| |
Collapse
|
10
|
Radocha J, Hájek R, Brožová L, Pour L, Špička I, Minařík J, Gregora E, Jungová A, Jelínek T, Heindorfer A, Sýkora M, Maisnar V. Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis. Ann Hematol 2018; 98:951-962. [PMID: 30539278 DOI: 10.1007/s00277-018-3568-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Accepted: 11/26/2018] [Indexed: 11/24/2022]
Abstract
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age > 75, creatinine > 152 μmol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p < 0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65 years.
Collapse
Affiliation(s)
- J Radocha
- 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic. .,Czech Myeloma Group, Brno, Czech Republic.
| | - R Hájek
- Czech Myeloma Group, Brno, Czech Republic.,Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
| | - L Brožová
- Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - L Pour
- Czech Myeloma Group, Brno, Czech Republic.,Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine Masaryk Universtiy, University Hospital Brno, Brno, Czech Republic
| | - I Špička
- Czech Myeloma Group, Brno, Czech Republic.,1st Medical Department - Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic
| | - J Minařík
- Czech Myeloma Group, Brno, Czech Republic.,Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic
| | - E Gregora
- Czech Myeloma Group, Brno, Czech Republic.,Department of Internal Medicine and Hematology, 3rd Faculty of Medicine, Charles University, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - A Jungová
- Czech Myeloma Group, Brno, Czech Republic.,Hematology and Oncology Department, Charles University Hospital Pilsen, Prague, Czech Republic
| | - T Jelínek
- Czech Myeloma Group, Brno, Czech Republic.,Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
| | - A Heindorfer
- Czech Myeloma Group, Brno, Czech Republic.,Department of Clinical Hematology, Hospital Liberec, Liberec, Czech Republic
| | - M Sýkora
- Czech Myeloma Group, Brno, Czech Republic.,Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
| | - V Maisnar
- 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic.,Czech Myeloma Group, Brno, Czech Republic
| |
Collapse
|
11
|
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 2018; 32:1697-1712. [DOI: 10.1038/s41375-018-0142-9] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 04/03/2018] [Accepted: 04/09/2018] [Indexed: 12/27/2022]
|